Globus Medical, Inc. (GMED) Fair Value 2026

GMED · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.2 /10

32 fundamental signals · 10 models active

Value Trap Risk

SAFE (23/100)

Quick Summary — As of 2026-08-27, Globus Medical, Inc. (GMED) trades at $82.54, versus a $85.88 median fair value across its 10 active models — 4.0% above the current price. QOC: 9.2/10. Value Trap Risk: 23/100 (SAFE). 10/13 models active. Within that set, the Bayesian DCF component alone returns $105.73.

Key Facts

Ticker
GMED
Price
$82.54
Quality Score
9.2/10
Value Trap Risk
23/100
Models Active
10/13
Last Updated
Strength: First Chicago suggests +64.2% upside with 57% confidence
Risk: Limited model coverage (10/13) may reduce confidence

Is Globus Medical, Inc. (GMED) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Globus Medical, Inc. (GMED) appears fairly valued as of : the median of 10 independent fair value estimates is $85.88, within 4.0% of the current price of $82.54. Estimates range from $15.61 to $135.54. GMED scores 9.2/10 on fundamental quality and 23/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. GMED’s +4.0% gap is narrower than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Globus Medical, Inc. Stock in 2026? →

What Fair Value Does Each Model Give GMED?

10 Intrinsic Value Models vs. Current Price ($82.54)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $105.73 +28.1%
Ensemble · Low Conviction
 $76.34 -7.5%
Scenario · High Conviction
 $135.54 +64.2%
Intrinsic · High Conviction
 $42.20 -48.9%
Unlock the Full Matrix

Access 6 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is GMED's Fair Value Range?

Spread across 10 independent models · $15.61 to $135.54

CirclFi's 10 active models place Globus Medical, Inc. (GMED) between $15.61 and $135.54 per share, a spread of 140% of the median. The median of that range — $85.88 — is the fair value CirclFi publishes for GMED, against a current price of $82.54.

Low · Dynamic NAVHigh · First Chicago
$15.61median $85.88$135.54
Where the range comes from
Most bearish modelDynamic NAV$15.61
Most bullish modelFirst Chicago$135.54
Model agreement5 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for GMED. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on GMED, not a CirclFi price target. How each model works →

What Is Globus Medical, Inc. (GMED) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Globus Medical, Inc.'s intrinsic value is estimated at a median $85.88, showing conflicting signals at the current price of $82.54. While the median implied return is +4.0%, model disagreement is elevated with a gap of +145.3% between the most bullish and bearish estimates. The most optimistic model, First Chicago, places fair value at $135.54 (+64.2%), while Dynamic NAV — the most conservative — estimates $15.61 (-81.1%). This +145.3% gap reflects genuine analytical uncertainty about Globus Medical, Inc.'s intrinsic worth.

What Do the Models Say About GMED?

10 of 13 models are currently active for GMED. Of these, 5 models suggest upside while 5 models suggest overvaluation. Taken together, their median fair value for GMED is $85.88 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $105.73 on its own, implying +28.1% upside from the current price. See which stocks rank higher →

How Does GMED Rank in Medical Devices?

Among 157 Medical Devices stocks, GMED ranks #3 by Quality of Company score. CirclFi's QOC score of 9.2/10 evaluates 32 fundamental signals. A score of 9.2 places GMED in the top tier.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, Globus Medical, Inc. competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is GMED a Value Trap?

CirclFi's Value Trap algorithm assigns GMED a score of 23/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Globus Medical, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Globus Medical, Inc. is rated at 9.2/10. This elite-tier score ranks among the highest-quality businesses in our coverage universe.

The gap between the most bullish and bearish model spans +145.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GMED valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GMED's 10 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Globus Medical, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

9 related Medical Devices stocks with 13-model coverage

PODDInsulet CorporationQOC 9.6DXCMDexCom, Inc.QOC 9.2IRMDIRADIMED CORPORATIONQOC 9.8UFPTUFP Technologies, Inc.QOC 9.2ITOCiTonic Holdings Ltd.QOC 2.5TMDXTransMedics Group, Inc.QOC 9.2IARTIntegra LifeSciences Holdings CorporationQOC 7.1NSPRInspireMD, Inc.QOC 6.1MDAISpectral AI, Inc.QOC 5.1

Read investment analysis: PODD · DXCM · IRMD · UFPT · ITOC · TMDX · IART · NSPR · MDAI

Which Other Stocks Have a Similar Quality Score to GMED?

7 companies across all industries closest to GMED’s Quality of Company score of 9.2/10.

CTASCintas CorporationQOC 9.2APPFAppFolio, Inc.QOC 9.2AVPTAvePoint, Inc.QOC 9.2VRTVertiv Holdings CoQOC 9.2NRDSNerdWallet, Inc.QOC 9.2PDDPDD Holdings Inc.QOC 9.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CTAS · APPF · AVPT · VRT · NRDS · PDD · NVDA

Where Does GMED Sit in CirclFi's Medical Devices Rankings?

GMED is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Globus Medical, Inc.’s Valuation?

What is Globus Medical, Inc.'s intrinsic value in 2026?

CirclFi puts Globus Medical, Inc. (GMED)'s intrinsic value at $85.88 — the median of 10 independent model estimates as of 2026-08-27, ranging from $15.61 to $135.54. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $105.73 on its own. The Quality of Company score is 9.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GMED overvalued or undervalued right now?

At $82.54, 5 of 10 active models suggest GMED may be undervalued, while 5 indicate potential overvaluation. The median of all 10 fair value estimates is $85.88, within 4.0% of the current price of $82.54 — a consensus view that GMED is fairly valued. The assessment depends on which methodology best fits Globus Medical, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 9.2 mean for GMED?

Globus Medical, Inc.'s QOC of 9.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on GMED?

CirclFi analyzes GMED with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on GMED?

Of the 10 models currently active on GMED, First Chicago is the most bullish at $135.54 per share, and Dynamic NAV is the most bearish at $15.61. CirclFi's published fair value for GMED is the median of that range, $85.88, not either extreme. The gap between the two ends equals 140% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is GMED a value trap in 2026?

Globus Medical, Inc.'s Value Trap score is 23/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Globus Medical, Inc. (GMED) has a median fair value of $85.88 — within 4.0% of the current price of $82.54 — as of 2026-08-27.” Source: circlfi.com/stock/GMED/ · Methodology
Primary sources for this GMED valuation
  • Financial statements: Globus Medical, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001237831) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GMED as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on GMED.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

6 models hidden for GMED Unlock All 10 — $39/mo